See more : Wanbury Limited (WANBURY.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Humana Inc. (HUM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Humana Inc., a leading company in the Medical – Healthcare Plans industry within the Healthcare sector.
You may be interested
- Upper Street Marketing Inc. (UPPR) Income Statement Analysis – Financial Results
- Agilyx ASA (AGXXF) Income Statement Analysis – Financial Results
- Gateley (Holdings) Plc (GTLY.L) Income Statement Analysis – Financial Results
- Defiance Connective Technologies ETF (SIXG) Income Statement Analysis – Financial Results
- Max Sound Corporation (MAXD) Income Statement Analysis – Financial Results
Humana Inc. (HUM)
About Humana Inc.
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully insured medical and specialty health insurance benefits comprising dental, vision, and other supplemental health benefits; and administrative services only products to individuals and employer groups, as well as military services, such as TRICARE T2017 East Region contract. Further, it offers pharmacy solutions, provider services, and home solutions services, such as home health and other services to its health plan members, as well as to third parties. As of December 31, 2021, the company had approximately 17 million members in medical benefit plans, as well as approximately 5 million members in specialty products. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 | 1990 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 106.37B | 92.87B | 83.06B | 77.16B | 64.89B | 56.91B | 53.77B | 54.38B | 54.29B | 48.50B | 41.31B | 39.13B | 36.83B | 33.87B | 30.96B | 28.95B | 25.29B | 21.42B | 14.42B | 13.10B | 12.23B | 11.26B | 10.19B | 10.51B | 10.11B | 9.78B | 8.04B | 6.79B | 4.70B | 3.65B | 3.14B | 4.04B | 5.87B | 4.85B |
| Cost of Revenue | 13.19B | 12.67B | 10.12B | 10.05B | 7.38B | 7.53B | 6.57B | 7.28B | 7.32B | 7.64B | 6.36B | 5.83B | 5.40B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 93.19B | 80.20B | 72.94B | 67.10B | 57.51B | 49.39B | 47.20B | 47.10B | 46.97B | 40.86B | 34.96B | 33.30B | 31.44B | 33.87B | 30.96B | 28.95B | 25.29B | 21.42B | 14.42B | 13.10B | 12.23B | 11.26B | 10.19B | 10.51B | 10.11B | 9.78B | 8.04B | 6.79B | 4.70B | 3.65B | 3.14B | 4.04B | 5.87B | 4.85B |
| Gross Profit Ratio | 87.60% | 86.36% | 87.82% | 86.97% | 88.63% | 86.78% | 87.79% | 86.62% | 86.52% | 84.25% | 84.62% | 85.10% | 85.35% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 5.40B | 4.66B | 4.23B | 3.94B | 3.48B | 3.02B | 2.18B | 1.88B | 1.86B | 1.74B | 1.55B | 1.44B | 1.37B | 1.33B | 1.12B | 940.00M | 571.00M | 436.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 0.00 | 12.20B | 10.12B | 10.05B | 7.38B | 7.53B | 6.42B | 7.17B | 7.30B | 7.64B | 6.36B | 5.83B | 5.40B | 4.66B | 4.23B | 3.94B | 3.48B | 3.02B | 2.18B | 1.88B | 1.86B | 1.74B | 1.55B | 1.44B | 1.37B | 1.33B | 1.12B | 940.00M | 571.00M | 436.00M | 368.00M | 371.00M | 226.00M | 226.40M |
| Other Expenses | 102.36B | 76.87B | 69.20B | 62.15B | 53.80B | 47.10B | 43.09B | 45.47B | 44.38B | 38.50B | 32.90B | 31.28B | 29.09B | 27.08B | 24.81B | 23.93B | 20.46B | 17.57B | 11.80B | 10.79B | 10.01B | -12.77B | 8.44B | 8.93B | -11.85B | -10.86B | -8.86B | -7.70B | -4.97B | -3.81B | -3.36B | -4.11B | -5.44B | -4.48B |
| Operating Expenses | 102.36B | 89.07B | 79.32B | 72.20B | 61.18B | 54.62B | 49.51B | 52.64B | 51.67B | 46.14B | 39.25B | 37.11B | 34.49B | 31.74B | 29.04B | 27.87B | 23.93B | 20.59B | 13.98B | 12.67B | 11.86B | -11.03B | 9.99B | 10.37B | -10.48B | -9.53B | -7.75B | -6.76B | -4.40B | -3.37B | -2.99B | -3.74B | -5.21B | -4.25B |
| Cost & Expenses | 102.36B | 89.07B | 79.32B | 72.20B | 61.18B | 54.62B | 49.51B | 52.64B | 51.67B | 46.14B | 39.25B | 37.11B | 34.60B | 32.12B | 29.36B | 27.95B | 24.00B | 20.65B | 14.00B | 12.69B | 11.88B | 11.05B | 10.01B | 10.40B | 10.52B | 9.58B | 7.77B | 6.77B | 4.41B | 3.40B | 422.00M | 680.00M | 579.00M | 568.60M |
| Interest Income | 0.00 | 401.00M | 326.00M | 283.00M | 242.00M | 218.00M | 242.00M | 189.00M | 186.00M | 192.00M | 140.00M | 105.00M | 0.00 | 60.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 493.00M | 401.00M | 326.00M | 283.00M | 242.00M | 218.00M | 242.00M | 189.00M | 186.00M | 192.00M | 140.00M | 105.00M | 109.00M | 105.06M | 105.84M | 80.29M | 68.88M | 63.14M | 39.32M | 23.17M | 17.37M | 17.25M | 25.30M | 29.00M | 33.00M | 47.00M | 20.00M | 11.00M | 11.00M | 25.00M | 7.00M | 71.00M | 97.00M | 111.30M |
| Depreciation & Amortization | 917.00M | 845.00M | 713.00M | 616.00M | 575.00M | 534.00M | 485.00M | 465.00M | 447.00M | 449.00M | 426.00M | 338.00M | 303.00M | 262.91M | 250.27M | 220.35M | 184.81M | 148.60M | 128.86M | 117.79M | 126.78M | 120.73M | 171.02M | 147.00M | 124.00M | 128.00M | 108.00M | 98.00M | 70.00M | 50.00M | 47.00M | 238.00M | 256.00M | 230.90M |
| EBITDA | 4.93B | 4.68B | 4.34B | 5.45B | 4.17B | 2.85B | 4.75B | 2.21B | 3.06B | 2.81B | 2.49B | 2.35B | 2.54B | 2.12B | 1.85B | 1.29B | 1.47B | 910.68M | 550.57M | 533.64M | 488.86M | 347.92M | 369.91M | 290.00M | -247.45M | 331.00M | 128.00M | 116.00M | 81.00M | 307.00M | 54.00M | 309.00M | 353.00M | 342.20M |
| EBITDA Ratio | 4.63% | 5.00% | 5.37% | 7.22% | 6.61% | 4.97% | 8.83% | 4.06% | 5.64% | 5.80% | 6.02% | 6.02% | 6.89% | 5.94% | 5.98% | 4.19% | 5.83% | 4.25% | 3.82% | 4.07% | 3.86% | 2.94% | 3.47% | 2.48% | -2.77% | 3.38% | 4.70% | 1.71% | 7.61% | 8.40% | 88.05% | 89.07% | 94.49% | 93.04% |
| Operating Income | 4.01B | 3.80B | 3.75B | 4.96B | 3.71B | 2.29B | 4.26B | 1.74B | 2.62B | 2.36B | 2.06B | 2.02B | 2.24B | 1.75B | 1.60B | 992.85M | 1.29B | 762.09M | 421.71M | 415.85M | 344.72M | 209.93M | 183.08M | 114.00M | -404.00M | 203.00M | 270.00M | 18.00M | 288.00M | 257.00M | 2.72B | 3.36B | 5.29B | 4.28B |
| Operating Income Ratio | 3.77% | 4.09% | 4.51% | 6.42% | 5.72% | 4.03% | 7.93% | 3.20% | 4.82% | 4.87% | 4.99% | 5.15% | 6.07% | 5.17% | 5.17% | 3.43% | 5.10% | 3.56% | 2.92% | 3.17% | 2.82% | 1.86% | 1.80% | 1.08% | -3.99% | 2.08% | 3.36% | 0.27% | 6.13% | 7.03% | 86.55% | 83.18% | 90.13% | 88.28% |
| Total Other Income/Expenses | -630.00M | -232.00M | -391.00M | -386.00M | 264.00M | -1.04B | -242.00M | -189.00M | 84.00M | -192.00M | -140.00M | -105.00M | 5.29B | -105.06M | -105.84M | -80.29M | -68.69M | -63.45M | -20.41M | -23.17M | 0.00 | 0.00 | 0.00 | 0.00 | -404.84M | 203.08M | 0.00 | 0.00 | 0.00 | 257.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | 3.38B | 3.57B | 3.35B | 4.60B | 3.46B | 2.06B | 4.02B | 1.55B | 2.43B | 2.17B | 1.92B | 1.91B | 2.24B | 1.75B | 1.60B | 992.85M | 1.29B | 762.09M | 421.71M | 415.85M | 344.72M | 209.93M | 183.08M | 114.00M | -404.00M | 203.00M | 270.00M | 18.00M | 288.00M | 257.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 3.18% | 3.84% | 4.04% | 5.96% | 5.33% | 3.62% | 7.48% | 2.85% | 4.48% | 4.47% | 4.65% | 4.88% | 6.07% | 5.17% | 5.17% | 3.43% | 5.10% | 3.56% | 2.92% | 3.17% | 2.82% | 1.86% | 1.80% | 1.08% | -3.99% | 2.08% | 3.36% | 0.27% | 6.13% | 7.03% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 836.00M | 762.00M | 485.00M | 1.31B | 763.00M | 391.00M | 1.57B | 938.00M | 1.16B | 1.02B | 690.00M | 689.00M | 816.00M | 650.17M | 562.09M | 345.69M | 455.62M | 274.66M | 113.23M | 135.84M | 115.78M | 67.18M | 65.91M | 24.00M | -22.00M | 74.00M | 97.00M | 6.00M | 98.00M | 81.00M | 54.00M | 109.00M | 200.00M | 180.50M |
| Net Income | 2.49B | 2.81B | 2.93B | 3.37B | 2.71B | 1.68B | 2.45B | 614.00M | 1.28B | 1.15B | 1.23B | 1.22B | 1.42B | 1.10B | 1.04B | 647.15M | 833.68M | 487.42M | 308.48M | 280.01M | 228.93M | 142.76M | 117.17M | 90.00M | -382.00M | 129.00M | 173.00M | 12.00M | 190.00M | 176.00M | 89.00M | 122.70M | 355.00M | 309.60M |
| Net Income Ratio | 2.34% | 3.02% | 3.53% | 4.36% | 4.17% | 2.96% | 4.55% | 1.13% | 2.35% | 2.36% | 2.98% | 3.12% | 3.85% | 3.25% | 3.36% | 2.24% | 3.30% | 2.28% | 2.14% | 2.14% | 1.87% | 1.27% | 1.15% | 0.86% | -3.78% | 1.32% | 2.15% | 0.18% | 4.04% | 4.82% | 2.84% | 3.03% | 6.05% | 6.38% |
| EPS | 20.09 | 22.20 | 22.79 | 25.47 | 20.20 | 12.24 | 16.94 | 4.11 | 8.54 | 7.44 | 7.81 | 7.56 | 8.58 | 6.55 | 6.21 | 3.87 | 5.00 | 2.97 | 1.91 | 1.75 | 1.41 | 0.85 | 0.71 | 0.54 | -2.28 | 0.77 | 1.06 | 0.07 | 1.17 | 1.10 | 0.56 | 0.77 | 2.26 | 3.00 |
| EPS Diluted | 20.00 | 22.08 | 22.67 | 25.31 | 20.10 | 12.16 | 16.81 | 4.07 | 8.44 | 7.36 | 7.73 | 7.47 | 8.46 | 6.47 | 6.15 | 3.83 | 4.91 | 2.90 | 1.87 | 1.72 | 1.38 | 0.83 | 0.70 | 0.54 | -2.28 | 0.77 | 1.05 | 0.07 | 1.16 | 1.10 | 0.55 | 0.77 | 2.26 | 3.00 |
| Weighted Avg Shares Out | 123.87M | 126.42M | 128.69M | 132.20M | 134.05M | 137.49M | 144.49M | 149.37M | 149.45M | 154.19M | 157.50M | 161.48M | 165.41M | 167.78M | 167.36M | 167.17M | 166.87M | 164.12M | 161.51M | 160.01M | 158.68M | 167.95M | 165.03M | 166.76M | 167.73M | 167.48M | 163.41M | 162.53M | 162.27M | 160.00M | 158.93M | 159.35M | 157.08M | 101.13M |
| Weighted Avg Shares Out (Dil) | 124.44M | 127.09M | 129.40M | 133.01M | 134.73M | 138.40M | 145.58M | 150.92M | 151.14M | 155.87M | 159.15M | 163.46M | 167.83M | 169.80M | 169.07M | 168.97M | 169.82M | 168.08M | 164.96M | 162.80M | 162.13M | 171.99M | 167.39M | 166.76M | 167.73M | 167.48M | 165.84M | 165.28M | 164.59M | 160.79M | 161.82M | 159.35M | 157.08M | 101.13M |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK, NY / ACCESSWIRE / October 27, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
The Schall Law Firm Urges Shareholder Participation In An Inquiry Into Humana Inc For Securities Law Violations
LOS ANGELES, CA / ACCESSWIRE / October 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations...
Bronstein, Gewirtz & Grossman, LLC Encourages Humana Inc. (HUM) Shareholders to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / October 27, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Humana Inc. ("Humana" or "the Company") (NYSE:HUM). Investors who purchased Humana securities are encouraged to...
Humana Inc. Is Being Investigated For Securities Fraud And Investors With Losses Are Encouraged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / October 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Humana Inc. ("Humana" or "the Company") (NYSE:HUM) for violations...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK, NY / ACCESSWIRE / October 25, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK, NY / ACCESSWIRE / October 25, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK , Oct. 25, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE: HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Humana Named “Best-of-the-Best” Company for Supplier Diversity by the National LGBT Chamber of Commerce
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana Named “Best-of-the-Best” Company for Supplier Diversity by the National LGBT Chamber of Commerce.
Humana and Longevity Health Multi-State Agreement Expands Access to Humana Together in Health Special Needs Plans
LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana and Longevity Health multi-state agreement expands access to Humana Together in Health, a Medicare Advantage Institutional Special Needs Plan.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Humana Inc. - HUM
NEW YORK, NY / ACCESSWIRE / October 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Humana Inc. ("Humana" or the "Company") (NYSE:HUM). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Source: https://incomestatements.info
Category: Stock Reports